Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $43.80.

Several research analysts have recently issued reports on COLL shares. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Needham & Company LLC reissued a “buy” rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Piper Sandler restated a “neutral” rating and issued a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Finally, StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 19th.

Collegium Pharmaceutical Stock Up 3.0%

Shares of NASDAQ:COLL opened at $30.23 on Friday. Collegium Pharmaceutical has a 52-week low of $23.23 and a 52-week high of $42.29. The company has a market capitalization of $971.35 million, a PE ratio of 13.03 and a beta of 0.63. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company has a fifty day moving average of $28.12 and a 200-day moving average of $29.85.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts’ consensus estimates of $1.50 by ($0.01). The firm had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company’s revenue was up 22.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.45 EPS. On average, equities analysts predict that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 2,255 shares of the stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the sale, the executive vice president now directly owns 124,421 shares in the company, valued at approximately $3,732,630. This trade represents a 1.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $28.50, for a total value of $742,909.50. Following the completion of the transaction, the executive vice president now directly owns 108,137 shares of the company’s stock, valued at approximately $3,081,904.50. This trade represents a 19.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,693 shares of company stock valued at $2,334,994 over the last ninety days. 2.51% of the stock is owned by company insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in the business. Uniplan Investment Counsel Inc. increased its holdings in Collegium Pharmaceutical by 0.6% in the first quarter. Uniplan Investment Counsel Inc. now owns 142,801 shares of the specialty pharmaceutical company’s stock worth $4,263,000 after purchasing an additional 797 shares in the last quarter. Millennium Management LLC grew its position in shares of Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after buying an additional 461,914 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Collegium Pharmaceutical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock valued at $569,000 after acquiring an additional 825 shares in the last quarter. Amundi lifted its position in shares of Collegium Pharmaceutical by 302.1% during the 1st quarter. Amundi now owns 62,592 shares of the specialty pharmaceutical company’s stock valued at $1,816,000 after acquiring an additional 47,024 shares during the period. Finally, Stonepine Capital Management LLC bought a new position in Collegium Pharmaceutical during the first quarter worth $615,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.